|Over a month ago|
Quanterix price target raised to $85 from $75 at SVB Leerink » 08:5103/0303/03/21
SVB Leerink analyst…
SVB Leerink analyst Puneet Souda raised the firm's price target on Quanterix to $85 from $75 and keeps an Outperform rating on the shares following quarterly results. The analyst argues the company is delivering a conservative 30%-40% revenue CAGR profile over the next three years and deriving nearly 60% of its revenues from biopharma customers that are willing to pay a premium for Quanterix's improved sensitivity.
Quanterix price target raised to $90 from $86 at Canaccord » 07:1203/0303/03/21
Canaccord analyst Max…
Canaccord analyst Max Mascucci raised the firm's price target on Quanterix to $90 from $86 and keeps a Buy rating on the shares. The analyst noted the company delivered Q4 results that matched its preannouncement and provided updates that support its multi-year runway in both research and clinical markets.
Fly Intel: After-Hours Movers » 19:1603/0203/02/21
MRVI, AMBA, QTRX, LYFT, FUBO, BGS, GO, VEC, ROST, NVEE, REAL, RVMD, JWN, URBN, ARNA, SSYS, ICAD, ABNB
Check out this evening's…
Quanterix reports Q4 loss from operations ($11.7M) vs. ($10.8M) last year » 16:0703/0203/02/21
Reports Q4 revenue…
Reports Q4 revenue $26.1M, consensus $23.44M. "Responding to the pandemic crisis as well as advances in therapies to treat Alzheimer's has accelerated our leadership of precision health and the proteomics revolution," said CEO, Kevin Hrusovsky. "There is a strong demand for ultra-sensitive protein analytical tools to support disease studies, diagnostics and drug development as the COVID focus shifts from battling the acute virus to the long-hauler impact of the virus on organ and overall human health. We enter 2021 on strong footing as we scale Quanterix to support this unprecedented opportunity."
Quanterix announces Simoa joint laboratory with WuXi AppTec » 14:1202/1202/12/21
Quanterix announced it…
Quanterix announced it has entered into an agreement to open a joint Simoa laboratory with WuXi AppTec to improve access to Quanterix' "industry leading" biomarker testing and development offerings across China and the APAC market. The Simoa Joint Lab is the strategic partnership between the two companies and will be established at WuXi AppTec's Shanghai facility. "The facility will leverage Quanterix' ultra-sensitive Simoa HD-X Analyzers, consumables resources and technical expertise to advance essential pre-clinical and clinical research in the region," the company said. Kevin Hrusovsky, Chairman, CEO and President of Quanterix, added: "We're excited to provide access to Simoa technology to the APAC region. This partnership enables us to offer even deeper support to our customers in this region and is a testament to the passion and collaboration that is taking place across the world to eradicate disease and empower true precision health."
Quanterix 3.6M share Spot Secondary priced at $70.00 » 07:1902/0402/04/21
The deal size was…
The deal size was increased to $250M in stock from $200M in stock and the range was $68.00-$71.00. Goldman Sachs, SVB Leerink and Cowen acted as joint book running managers for the offering.
Quanterix $200M Spot Secondary; price range $68.00-$71.00 » 17:0402/0302/03/21
Goldman Sachs, SVB…
Goldman Sachs, SVB Leerink and Cowen are acting as joint book running managers for the offering.
Quanterix announces offering of $200M of common stock offering » 16:2702/0302/03/21
Quanterix Corporation announced that it has commenced an underwritten public offering of $200M of its common stock. Goldman Sachs & Co., SVB Leerink, and Cowen and Company are acting as joint bookrunning managers for the offering. Canaccord Genuity is acting as lead manager for the offering.
Quanterix price target raised to $75 from $50 at SVB Leerink » 09:1301/2701/27/21
SVB Leerink analyst…
SVB Leerink analyst Puneet Souda raised the firm's price target on Quanterix to $75 from $50 and keeps an Outperform rating on the shares. The analyst cites preliminary Q4 results and his revised outlook on 2021. Souda believes core to Quanterix's success is its neurology immunoassay franchise which is driving growth in clinical trials as Alzheimer's and other disorders are pursued and research into neurology grows further. He also recognizes that Quanterix's Simoa platform is levered to targeted proteomics.
Quanterix price target raised to $74 from $60 at Canaccord » 07:2401/1401/14/21
Canaccord analyst Max…
Canaccord analyst Max Mascucci raised the firm's price target on Quanterix to $74 from $60 and keeps a Buy rating on the shares. The analyst noted its solid Q4 preannouncement revenue beat which demonstrated resilience and strength in its core research business. He expects its inclusion in the field of proteomics will mirror its success and advancement seen in the filed of genomics over the past 10 years.